HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Pulmonary Heart Disease (Cor Pulmonale)

Hypertrophy and dilation of the RIGHT VENTRICLE of the heart that is caused by PULMONARY HYPERTENSION. This condition is often associated with pulmonary parenchymal or vascular diseases, such as CHRONIC OBSTRUCTIVE PULMONARY DISEASE and PULMONARY EMBOLISM.
Also Known As:
Cor Pulmonale; Pulmonary Heart Diseases; Disease, Pulmonary Heart; Diseases, Pulmonary Heart; Heart Disease, Pulmonary; Heart Diseases, Pulmonary
Networked: 840 relevant articles (34 outcomes, 67 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1. Chronic Obstructive Pulmonary Disease (COPD)
2. Heart Failure
3. Pulmonary Hypertension (Ayerza Syndrome)
4. Bronchitis
5. Airway Obstruction (Choking)

Experts

1. Weissmann, Norbert: 4 articles (10/2008 - 01/2004)
2. Grimminger, Friedrich: 4 articles (10/2008 - 01/2004)
3. Seeger, Werner: 4 articles (10/2008 - 01/2004)
4. Butorov, I V: 4 articles (01/2008 - 01/2003)
5. Butorov, S I: 4 articles (01/2008 - 01/2005)
6. Belló-Klein, Adriane: 3 articles (09/2015 - 08/2008)
7. Vieillard-Baron, Antoine: 3 articles (01/2015 - 02/2011)
8. Shen, Jun-li: 3 articles (07/2009 - 06/2005)
9. Yang, Sheng-yue: 3 articles (07/2009 - 06/2005)
10. Feng, En-zhi: 3 articles (07/2009 - 06/2005)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Pulmonary Heart Disease:
1. OxygenIBA
2. Amrinone (Amrinon)FDA Link
3. Digoxin (Digitek)FDA LinkGeneric
4. Idiopathic pulmonary hypertensionIBA
5. Theophylline (Theon)FDA LinkGeneric
6. Angiotensin IIIBA
7. Ramipril (Altace)FDA LinkGeneric
8. olmesartan medoxomil (Votum)FDA Link
9. Hydralazine (Apresoline)FDA LinkGeneric
10. Captopril (Capoten)FDA LinkGeneric

Therapies and Procedures

1. Catheters
2. Tracheostomy
3. Aftercare (After-Treatment)
12/01/1994 - "The results showed that ET-1 level was significantly higher in cor pulmonale patients (P < 0.001) and decreased significantly after treatment (P < 0.001), but was still higher than that in controls (P < 0.002). "
01/01/1971 - "Dynamics of heart contraction in chronic cor pulmonale with heart failure II-a Degree before and after treatment as revealed through phase analysis of the mechanical systole."
09/01/1999 - "Indices were studied for the right and left ventricular performance in 15 patients with chronic cor pulmonale before and after treatment with tekom containing above 43% of omega-3 polyunsaturated fatty acids. "
10/01/1991 - "Heparin intravenous drip induced ATIII decreased; (2) the level of ATIII:A in patients with heparin vapour inhalation treatment was significantly higher than that with regular treatment and with heparin intravenous drip (P less than 0.05) and (P less than 0.005); (3) SM presents ATIII-like activity, after treatment with SM, the level of ATIII:A was significantly higher than that with heparin vapour inhalation, heparin intravenous drip and regular treatment (P less than 0.05-0.005), heparin may enhance the ATIII-like activity of SM; (4) the treatment combining SM intravenous drip with heparin vapour inhalation is an efficient therapy of anticoagulation on the patients with cor pulmonale. "
08/01/1976 - "After treatment for cor pulmonale theophylline clearance improved; however, with the subsequent onset of fever and pneumonia the clearance decreased again, illustrating the potential lability of theophylline clearance."
4. Tonsillectomy
5. Adenoidectomy